• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    Q BioMed Inks Strontium89 Supply Pact

    PCI Pharma Services Appoints SVP, CFO
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Completes OXGENE Acquisition

    Celonic Group Announces Plans for New Facility in Switzerland

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    WuXi AppTec Completes OXGENE Acquisition

    Live Webinar - Formulation Strategies for Poorly Soluble Molecules

    Celonic Group Announces Plans for New Facility in Switzerland
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Cytovance Biologics

    Emergent BioSolutions

    Syngene

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Adare Pharma Solutions

    Baxter BioPharma Solutions

    Alcami

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Pharma Beat

    Tackling TB Resistance

    The TB Alliance is partnering with universities, government agencies, public agencies and a small number of pharma compani

    Tackling TB Resistance
    Related CONTENT
    • Frontida BioPharm Launches Expansion Efforts
    • The FDA and Metrics
    • WHO Lauds India’s Vaccine Safety
    • Could Nuts Ward Off Cancer?
    • Generic Drug Trends
    Adele Graham-King, Contributing Editor05.09.17
    Tuberculosis (TB) is a pandemic disease, which has affected human beings for centuries. Documented through the ancient civilizations of India and China, and traced across the globe through the Middle Ages, the killer infection has been given various different names including ‘consumption’ and the White Plague. Consumption is one of the most common definitions due to the dramatic weight loss that is observed through the loss of appetite and persistent coughing, which are clear signs of the disease.

    Caused by the bacteria Mycobacterium tuberculosis, it’s an infection that is spread between humans by airborne transfer of the bacteria through coughing, sneezing or even just speaking to one another. Historically through the 17th to 19th Centuries it was a disease considered to be a pauper problem with a self-blame image of the working classes who lived in crowded conditions. Combined with the industrial revolution, these conditions provided a perfect environment for the bacterial killer to spread rapidly and effectively. Primarily affecting the lungs, although extra-pulmonary TB can also occur, other clinical observations are night sweats, fever, chills and fatigue.

    It wasn’t until 1944 and the discovery of streptomycin that there was an antibiotic treatment for consumption following many failed efforts of treatment through containment and isolation. This was followed in the 1950s with the development of Isoniazid—a mycobactericidal compound—and the antibiotic Rifampicin in the 1970s. At the same time as pharmacological therapies were emerging, scientists had been actively working to develop vaccines. In 1906 French development scientists created the first effective vaccine aptly named the BCG (Bacille Calmette-Guérin) after the creators. Although this was used in France in the early 1920s it wasn’t taken on board further afield until the late 1940s and 1950s. Ironically, although there have been attempts to find alternative vaccinations, to this day this is still the only vaccine available for the prevention of TB.

    Since the development of the BCG vaccine it has been widely used globally and it’s currently estimated to be delivered to 80% of newly born babies across the world. It had been hoped that it would be feasible to eradicate this awful killer, but although there has been a rapid decline in deaths in the developed world, the World Health Organization (WHO) declared a global health emergency in 1993 and again in Africa in 2005 following resurgence of multidrug resistant strains of the bacteria in the 1980s. In addition, with the arrival of HIV around the same time frame there is now an established link with the risk of developing TB and the virus—it is 26-31 times greater in these patients. Bearing in mind the prevalence of HIV in Africa and other parts of the developing world it’s clear to see why TB has reared its ugly head again with a vengeance.

    Currently, according the WHO, TB remains one of the top 10 causes of death worldwide with 1.4 million deaths attributed to it in 2015 and 10.4 million becoming ill. In the same year almost 90% of cases occurred in 6 countries in Asia and Africa and almost half a million people are suspected of suffering from multidrug resistant TB (MDR-TB) strains.

    Standard treatment regimens generally comprise of four anti-TB drugs—isoniazid, rifampicin and a fluoroquinolone—to be taken over a period of 6 months. Recurrence of the disease is treated by four, if not more effective antibiotics for a period of 18-24 months. However over recent years the bacteria has mutated even more so and newer definitions of extensively drug-resistant TB—XDR-TB is resistant to three or more TB drugs—and in the past 10 years totally drug-resistant TB have emerged. Something has to be done in order to reach the goal of the WHO to beat the world TB epidemic by the end of 2030.

    The TB Alliance is a not-for-profit organization dedicated to the discovery and development of better, faster-acting, and affordable tuberculosis drugs that are available to those who need them. It is a funded agency, which relies on support of donors to fund its development work that includes the FDA and USAID. Working in partnership with universities, government agencies, public agencies and a small number of pharma companies, it aims to develop new TB drugs alongside maximizing the treatment regimens of established drug entities. Although TB is still at global pandemic levels there are fewer than 20 known compounds with activity against mycobacterium, which leaves a massive hole in a therapy area where resistance is well known to be increasing.

    One of the established partnerships of the TB Alliance is between John Hopkins University (Baltimore) and the Medicines Patent Pool (MPP), which is a UN-backed organization supporting development and access to medicines for poorer countries in the specific areas of HIV, Hep-C and TB. Of late, the partnership has been working together to clinically develop Sutezolid, a drug candidate which has demonstrated interesting activity in combination with other TB drugs in treatment of the condition. Sutezolid is an oxazolidinone, the same class of drug as linezolid, which is also under investigation by the TB Alliance in early Phase II and Phase III clinical trials. In some ways it’s absurd that there are so few treatment options for TB which is a globally devastating condition, however it looks like the alliance combined with the MPP are making progress.

    In March 2017 the MPP announced a sublicensing agreement for the clinical development of Sutezolid in partnership with the TB Alliance and the patent owner John Hopkins University. Using the combination of the other known licensed drugs that are acknowledged to have activity against the mycobacterium has great potential to provide another treatment against XDR-TB, which is becoming increasingly difficult to combat and unfortunately increasingly common. The license, which the MPP holds now gives them the rights to approach interested parties to investigate the possibilities of developing treatments for both sensitive and resistant TB strains and to look at combinations with other drug entities to create new multi-pronged attacks on the bacteria.

    In line with further work from the TB Alliance who have Phase I, II, III & IV trials ongoing using a mix of pharmaceutical agents including Ethambutol, Pyrazinamide, Isoniazid, Pretomanid, Moxifoxacin, Linezolid and Bedaquiline, the outlook for identifying new treatments looks very positive, regardless of identification of new drug entities. Several of these drugs are listed on the WHO’s List of Essential Medicines and are generic, cost effective medicines with simple routes of administration, which is in line with the TB Alliance strategy to be successful in developing better, faster-acting, and affordable tuberculosis drugs that are available to those who need them. Alongside activities such as the MPP-TB Alliance project, they are hopefully well on track to hit their target of beating TB by 2030.


    Adele Graham-King
    Contributing Editor

    Adele is a design consultant who works in product development for medical and healthcare applications. Her background is in pharma, and she has a degree in applied physiology.
    Related Searches
    • Development
    • license
    • china
    • Vaccine
    Suggested For You
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    The FDA and Metrics The FDA and Metrics
    WHO Lauds India’s Vaccine Safety WHO Lauds India’s Vaccine Safety
    Could Nuts Ward Off Cancer? Could Nuts Ward Off Cancer?
    Generic Drug Trends Generic Drug Trends
    The Trials and Tribulations  of Male Contraception The Trials and Tribulations of Male Contraception
    LSNE Completes Two FDA Inspections LSNE Completes Two FDA Inspections
    ‘Smart’ Heparin Delivery Could Self-Modulate ‘Smart’ Heparin Delivery Could Self-Modulate
    FDA’s Quality Agreements Guidance FDA’s Quality Agreements Guidance
    IDT Biologika Establishes Animal Health Biz in U.S. IDT Biologika Establishes Animal Health Biz in U.S.
    Trends Affecting the Generic Drugs Sector in 2017 Trends Affecting the Generic Drugs Sector in 2017
    Novasep Custom Mfg. Sites Complete FDA Inspections Novasep Custom Mfg. Sites Complete FDA Inspections
    Genentech Extends Phylogica Research Pact Genentech Extends Phylogica Research Pact

    Related Pharma Beat

    • Drug Development

      NSAIDs – Friend or Foe?

      Although widely used for years, NSAIDs have side effects that could eventually change their OTC status
      Adele Graham-King, Contributing Editor 06.06.17

    • Drug Development

      Could Nuts Ward Off Cancer?

      Recent research looks into the anti-cancer properties of various nuts
      Adele Graham-King, Contributing Editor 04.03.17

    • Drug Delivery | Drug Development | R&D

      ‘Smart’ Heparin Delivery Could Self-Modulate

      A group of researchers have spent the past two years investigating self-controlling dosing and monitoring systems
      Adele Graham-King, Contributing Editor 01.26.17


    • Drug Development | Drug Discovery | R&D

      Is Nicotine Such a ‘Bad Boy’?

      Investigating this controversial compound’s potential health benefits
      Adele Graham-King, Contributing Editor 11.09.16

    • Drug Development | Drug Discovery | R&D

      Blackberry Wine: Could it Help Your Diabetes?

      Recent research points towards the positive impact ‘berry wine’ might have on diabetes
      Adele Graham-King, Contributing Editor 10.11.16

    • Chemistry | Drug Development
      Anyone Fancy a Beer?

      Anyone Fancy a Beer?

      The centuries-old brew continues to be investigated for its medicinal properties
      Adele Graham-King, Contributing Editor 05.05.16


    • Drug Development

      Chipping Away at the Old Cancer Block

      Advances in cancer treatment continue to march towards finding a cure
      Adele Graham-King, Contributing Editor 04.05.16

    • Clinical Trials | Drug Development

      The 3D Printed Pill

      It’s the future…or is it?
      Adele Graham-King, Contributing Editor 01.28.16

    • Clinical Trials | Drug Development | Drug Discovery | R&D

      Are We There Yet?

      Many promising cancer treatments are on the horizon
      Adele Graham-King, Contributing Editor 07.14.15


    • APIs | Bioassay Development | Drug Development | Methods Development | Process Development | Toxicology

      The Last Chance Saloon?

      Looking at the pharmaceutical ‘diet’ of anti-obesity drugs
      Adele Graham-King, Contributing Editor 06.02.15

    • Clinical Trials | Drug Development

      100 New Drugs in 10 Years?

      Repurposing drug candidates that never saw the light of day
      Adele Graham-King, Contributing Editor 03.06.15

    • APIs | Bioassay Development | Clinical Trials | Drug Development | Drug Discovery | Methods Development | Process Development | R&D | Toxicology

      Experimental Drugs

      To use or not to use unlicensed drugs? That is the question.
      Adele Graham-King, Contributing Editor 01.29.15


    • Drug Delivery | Drug Development
      The End of a Century

      The End of a Century

      Looking at 15 years of pharmaceutical evolution.
      Adele Graham-King 10.14.14

    • Drug Discovery

      Under the Sea: The Search for New Cures in the “Post-Antibiotic” Era

      A new WHO report raises some frightening questions on antimicrobial resistance, while Scotland’s PharmaSea Project looks for answers in the oceans’ depths
      Adele Graham-King 07.21.14

    • Chemistry | Drug Discovery | Supply Chain

      Toward a Process-Centered Pharma

      Saying “No” to change is normal, but adopting true QbD practices could save the industry about 20-25% of its global revenue and allow pharma to add two to three billion patients to its customer base
      Girish Malhotra, EPCOT International 06.03.14

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    • Alimentiv Acquires McDougall Scientific
    • Q BioMed Inks Strontium89 Supply Pact
    • PCI Pharma Services Appoints SVP, CFO
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    AHPA Submits Comments to FDA on Proposed Traceability Rule
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    AOC Announces EMEA Price Increase
    Mule-Hide Products Co. Introduces Seal-Fast Liqui-Flash
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    NAMSA Acquires American Preclinical Services
    Quidel's QuickVue At-Home COVID-19 Test Earns EUA
    Memic Receives FDA Marketing Authorization for Hominis
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial
    Alimentiv Acquires McDougall Scientific
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    IT Cosmetics Supports Women’s Confidence
    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Happi

    Latest Breaking News From Happi

    Croda International Acquires Alban Muller
    Givaudan Active Beauty Launches Omegablue
    Sozio Acquires Scentessence
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Abbott Label installs Domino K600i dual bar digital UV inkjet printer
    Crossmark turns to Eagle Systems for cold foil
    Maxcess launches Tidland PressureMax Airshaft Pressure Monitoring System
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Domtar Completes Sale of Personal Care Business
    Mitsui to Sell Chinese Nonwovens Business
    Dr. J's Disinfectant Wipes Approved for Distribution in CA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    SeaSpine Releases Reef TO (TLIF Oblique) Interbody System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login